Trial of Deferiprone in Parkinson’s Disease

J 2022

Trial of Deferiprone in Parkinson’s Disease

DEVOS, D., J. LABREUCHE, O. RASCOL, J.-C. CORVOL, A. DUHAMEL et. al.

Základní údaje

Originální název

Trial of Deferiprone in Parkinson’s Disease

Autoři

DEVOS, D., J. LABREUCHE, O. RASCOL, J.-C. CORVOL, A. DUHAMEL, P. Guyon DELANNOY, W. POEWE, Y. COMPTA, N. PAVESE, E. RŮŽIČKA, P. DUŠEK a B. POST

Vydání

The New England Journal of medicine, USA, Massachusetts Medical Society, 2022, 1533-4406

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

FAIRPARK II

Impakt faktor

Impact factor: 158.500

Kód RIV

RIV/00216224:14110/22:00127673

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1056/NEJMoa2209254

UT WoS

000898926800010

Klíčová slova česky

Parkinsonova choroba ;neurodegenerativní porucha ;FAIRPAK II ;klinické hodnocení

Klíčová slova anglicky

Parkinson’s Disease ;neurodegenerative disorder ;FAIRPAK II ;clinical trial

Štítky

MU, RIV, UK LF PRAHA, UK PRAHA, user

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 10. 2024 15:10, Mgr. Natálie Hílek

Anotace

V originále

BACKGROUND Iron content is increased in the substantia nigra of persons with Parkinson’s disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson’s disease, but its effects on disease progression are unclear.

Návaznosti

90128, velká výzkumná infrastruktura

Název: CZECRIN III

Citovat

DEVOS, D., J. LABREUCHE, O. RASCOL, J.-C. CORVOL, A. DUHAMEL, P. Guyon DELANNOY, W. POEWE, Y. COMPTA, N. PAVESE, E. RŮŽIČKA, P. DUŠEK a B. POST. Trial of Deferiprone in Parkinson’s Disease. The New England Journal of medicine. USA: Massachusetts Medical Society, 2022, roč. 387, NA, s. 2045-2055. ISSN 1533-4406. Dostupné z: https://dx.doi.org/10.1056/NEJMoa2209254.

@article{2243480,
   author = {DEVOS, D. and LABREUCHE, J. and RASCOL, O. and CORVOL, J.andC. and DUHAMEL, A. and DELANNOY, P. Guyon and POEWE, W. and COMPTA, Y. and PAVESE, N. and RŮŽIČKA, E. and DUŠEK, P. and POST, B.},
   article_location = {USA},
   article_number = {NA},
   doi = {http://dx.doi.org/10.1056/NEJMoa2209254},
   keywords = {Parkinson’s Disease ;neurodegenerative disorder ;FAIRPAK II ;clinical trial},
   language = {eng},
   issn = {1533-4406},
   journal = {The New England Journal of medicine},
   title = {Trial of Deferiprone in Parkinson’s Disease},
   url = {https://www.nejm.org/doi/full/10.1056/NEJMoa2209254},
   volume = {387},
   year = {2022}
}

TY  - JOUR
ID  - 2243480
AU  - DEVOS, D. - LABREUCHE, J. - RASCOL, O. - CORVOL, J.-C. - DUHAMEL, A. - DELANNOY, P. Guyon - POEWE, W. - COMPTA, Y. - PAVESE, N. - RŮŽIČKA, E. - DUŠEK, P. - POST, B.
PY  - 2022
TI  - Trial of Deferiprone in Parkinson’s Disease
JF  - The New England Journal of medicine
VL  - 387
IS  - NA
SP  - 2045-2055
EP  - 2045-2055
PB  - Massachusetts Medical Society
SN  - 15334406
KW  - Parkinson’s Disease ;neurodegenerative disorder ;FAIRPAK II ;clinical trial
UR  - https://www.nejm.org/doi/full/10.1056/NEJMoa2209254
N2  - BACKGROUND Iron content is increased in the substantia nigra of persons with Parkinson’s disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson’s disease, but its effects on disease progression are unclear.
ER  -

DEVOS, D., J. LABREUCHE, O. RASCOL, J.-C. CORVOL, A. DUHAMEL, P. Guyon DELANNOY, W. POEWE, Y. COMPTA, N. PAVESE, E. RŮŽIČKA, P. DUŠEK a B. POST. Trial of Deferiprone in Parkinson’s Disease. \textit{The New England Journal of medicine}. USA: Massachusetts Medical Society, 2022, roč.~387, NA, s.~2045-2055. ISSN~1533-4406. Dostupné z: https://dx.doi.org/10.1056/NEJMoa2209254.

Podrobný výpis o publikaci